Literature DB >> 23092812

Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children.

Imke Heleen Bartelink1, Svetlana V Belitser, Catherijne A J Knibbe, Meindert Danhof, Anne J de Pagter, Toine C G Egberts, Jaap Jan Boelens.   

Abstract

The severity of complications of allogeneic hematopoietic stem cell transplantation (HSCT) is governed mainly by the status of immune reconstitution. In this study, we investigated differences in immune reconstitution with different cell sources and the association between the kinetics of immune reconstitution and mortality. Immunophenotyping was performed every 2 weeks in children who had undergone HSCT between 2004 and 2008 at University Medical Center Utrecht. Lymphocyte reconstitution in the first 90 days after HSCT was studied in relation to mortality in 3 HSCT groups: matched sibling bone marrow (BM) recipients (35 patients), unrelated BM recipients (32 patients), and unrelated cord blood recipients (36 patients). The median age of recipients was 5.9 years (range, 0.1-21 years). The nature and speed of T cell, B cell, and natural killer (NK) cell reconstitution were highly dependent on the cell source. In the first 90 days after HSCT, faster B cell and NK cell reconstitution and delayed T cell reconstitution were shown in unrelated cord blood recipients compared with matched sibling BM and unrelated BM recipients. Of the lymphocyte subsets investigated, a large number of NK cells and a more rapid CD4(+) immune reconstitution over time, resulting in sustained higher CD4(+) counts, were the only predictors of a lower mortality risk in all cell sources. The final model showed that during the first 90 days, patients with an area under the CD4(+) cell receiver- operating curve of >4,300 cells/day and no peak in CD4(+) cell counts had the highest likelihood of survival (hazard ratio for mortality, 0.2; 95% confidence interval, 0.06-0.5). Our data indicate that CD4(+) kinetics may be used to identify patients at greatest risk for mortality early after HSCT.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23092812     DOI: 10.1016/j.bbmt.2012.10.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  36 in total

1.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Authors:  Gunjan L Shah; Leyla Shune; Duncan Purtill; Sean Devlin; Emily Lauer; Marissa Lubin; Valkal Bhatt; Courtney McElrath; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Miguel A Perales; Doris M Ponce; James W Young; Monica Shah; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-10       Impact factor: 5.742

2.  Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.

Authors:  Amir A Toor; Roy T Sabo; Catherine H Roberts; Bonny L Moore; Salman R Salman; Allison F Scalora; May T Aziz; Ali S Shubar Ali; Charles E Hall; Jeremy Meier; Radhika M Thorn; Elaine Wang; Shiyu Song; Kristin Miller; Kathryn Rizzo; William B Clark; John M McCarty; Harold M Chung; Masoud H Manjili; Michael C Neale
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

Review 3.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

4.  Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation.

Authors:  K Nakatani; K Imai; M Shigeno; H Sato; M Tezuka; T Okawa; N Mitsuiki; T Isoda; D Tomizawa; M Takagi; M Nagasawa; M Kajiwara; M Yamamoto; A Arai; O Miura; C Kamae; N Nakagawa; K Honma; S Nonoyama; S Mizutani; T Morio
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

5.  Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis.

Authors:  R Admiraal; R Chiesa; C A Lindemans; S Nierkens; M B Bierings; A B Versluijs; P Hiwarkar; J M Furtado Silva; P Veys; J J Boelens
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

6.  Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

Authors:  Coco de Koning; Julie-Anne Gabelich; Jurgen Langenhorst; Rick Admiraal; Jurgen Kuball; Jaap Jan Boelens; Stefan Nierkens
Journal:  Blood Adv       Date:  2018-03-13

7.  Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Authors:  Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker
Journal:  Blood Adv       Date:  2020-01-14

8.  Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Authors:  J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens
Journal:  Blood Adv       Date:  2019-07-23

9.  Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Authors:  Nelli Bejanyan; Claudio G Brunstein; Qing Cao; Aleksandr Lazaryan; Xianghua Luo; Julie Curtsinger; Rohtesh S Mehta; Erica Warlick; Sarah A Cooley; Bruce R Blazar; Jeffrey S Miller; Daniel Weisdorf; John E Wagner; Michael R Verneris
Journal:  Blood Adv       Date:  2018-04-24

10.  CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.

Authors:  Coco de Koning; Susan Prockop; Ichelle van Roessel; Nancy Kernan; Elizabeth Klein; Jurgen Langenhorst; Celina Szanto; Mirjam Belderbos; Marc Bierings; Farid Boulad; Dorine Bresters; Maria Cancio; Kevin Curran; Wouter Kollen; Richard O'Reilly; Andromachi Scaradavou; Barbara Spitzer; Birgitta Versluijs; Alwin Huitema; Caroline Lindemans; Stefan Nierkens; Jaap Jan Boelens
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.